<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081027</url>
  </required_header>
  <id_info>
    <org_study_id>CIN001- Riluzole in Autism</org_study_id>
    <nct_id>NCT02081027</nct_id>
  </id_info>
  <brief_title>Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if riluzole shows evidence of efficacy, safety, and tolerability targeting&#xD;
      drug-refractory irritability (DRI) in persons with autism spectrum disorders (ASD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, placebo-controlled, 12-week cross-over study (5-week treatment&#xD;
      periods with 2-week washout) of adjunctive riluzole in 12 persons with ASD and DRI between&#xD;
      the ages of 12 and 25 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Improvement</measure>
    <time_frame>Change from baseline to end of week 12</time_frame>
    <description>A clinician-rated global assessment of symptom change rated on a scale from 1 to 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aberrant Behavior Checklist- Irritability</measure>
    <time_frame>Change between baseline and end of each phase</time_frame>
    <description>A parent questionnaire measuring five behavioral domains</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum dose of riluzole to be used in this study is 200 mg per day divided BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <arm_group_label>Riluzole</arm_group_label>
    <other_name>Other name: Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 12 and &lt; 26 years.&#xD;
&#xD;
          -  Weight greater than 50 kg.&#xD;
&#xD;
          -  Diagnosis of ASD&#xD;
&#xD;
          -  Drug-refractory irritability, as defined as screening ABC Irritability subscale&#xD;
             (ABC-I) score of ≥18 AND 1) failure of clinically adequate treatment trials of both&#xD;
             aripiprazole and risperidone or 2) failure of at least three previous clinically&#xD;
             adequate drug trials targeting irritability (one trial must include aripiprazole or&#xD;
             risperidone), as confirmed by caregiver reports and medical record review when&#xD;
             available.&#xD;
&#xD;
          -  Stable dosing of all concomitant psychotropic medications (including those targeting&#xD;
             irritability) for four weeks prior to screening visit and during the study.&#xD;
&#xD;
          -  Presence of parent/guardian willing to serve as informant for behavioral outcome&#xD;
             measures and shipping control sample for Extracellular Signal-Related Kinase biomarker&#xD;
             (ERK) assay.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of more than two concomitant psychotropic drugs targeting irritability.&#xD;
&#xD;
          -  Current use of valproic acid.&#xD;
&#xD;
          -  Current use of drugs with known interaction with riluzole&#xD;
&#xD;
          -  Current use of drugs with concomitant glutamatergic or glutamatergic- modulating&#xD;
             action medications.&#xD;
&#xD;
          -  For female subjects of child bearing potential, a positive serum pregnancy test.&#xD;
&#xD;
          -  History of pancreatitis.&#xD;
&#xD;
          -  Hemoglobin less than or equal to 8.0 gm/dL.&#xD;
&#xD;
          -  Neutropenia with absolute neutrophil count less than or equal to 1.0 K/mcL.&#xD;
&#xD;
          -  Problems with kidney functioning, as assessed by lab work&#xD;
&#xD;
          -  Any major chronic medical or chronic respiratory illness considered to be uncontrolled&#xD;
             by the Principal Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Logan Wink, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1007/s10803-018-3562-5</url>
    <description>Journal of Autism and Developmental Disorders (2018) 48:3051-3060</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

